G Medical Innovations : Medical Company Presentation, April 2023

MEDICAL

April 2023

COMPANY PRESENTATION

Nasdaq: GMVD

Forward-Looking Statements

All statements in this presentation, other than those relating to historical facts, are "forward‐looking statements." Words such as "may," "will," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions or variations of such words are intended to identify forward- looking statements. For example, G Medical Innovations Holdings Ltd. (the "Company") is using forward-looking statements when it discusses its plans and expectations, its financial plans, its expected revenue models and generation,the potential of its technology and products, its strategy and its future growth. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's prospectus dated March 31,2023, filed with the Securities and Exchange Commission ("SEC") as part of the Company's Registration Statement on Form F-1, as amended (File No. 333-269496).Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

2

Company Overview

G Medical is a Next-GenerationTele-Health and At-Home Testing Company

• We develop and market clinical and consumer medical-grade remote monitoring systems focused on chronic diseases as well as develop and market at-home testing kits which will be delivered to and processed by our CLIA certified lab, once operational, which we expect to occur in Q2 2023.
• • We utilize sophisticated Deep Neural Networks based Artificial Intelligence (AI)-backed ECG software which is used as a powerful secondary analysis tool.
  • We have developed At-HomeTesting Kits to collect samples of blood, saliva, stool, urine, etc. to be used to detect a multitude of common and less common disorders. We expect to commence sales of the at-home testing kits during Q3 2023.
• We believe that we are at the forefront of the digital health and at-home testing revolution meant to empower consumers, patients and health care providers to better monitor, manage and improve clinical health outcomes.
• We focus on chronic diseases such as cardiovascular disease, pulmonary disease, diabetes and obesity.
• We have enjoyed $21 million in revenue from sales of our devices & monitoring services in the last 4 and a half years.
• 7 granted patents covering key aspects of our devices.

Digital health devices and monitoring

Reduce the Expense

in dollars and time in healthcare.

Digital health market projected at

$316.8 B by 2027

3

RecentDevelopments

Collaborations with MiCare Path and AdventHealth Central Florida Announced in March 2023

• Goal is to provide innovative remote patient monitoring solutions globally.
• The partnership aims to incorporate MiCare Path's optimized patient care platform and G Medical Innovations' mobile health and digital health solutions.
• Both companies aim to transform the healthcare industry by leveraging technology and providing patient-centered care.
• G Medical's innovative and scalable solution for health technology was a reason for their selection as a partner.
• The collaboration will allow for a total remote patient monitoring and remote therapeutic monitoring solution from service to exceptional future solutions.
• The integration of both companies' solutions will benefit physicians and patients, driving better outcomes across all services.

• Goal is to provide innovative remote patient monitoring solutions for AdventHealth patients in central Florida.
• The agreement aims to expand AdventHealth's remote patient monitoring capabilities.
• G Medical will provide Prizma devices for remote patient monitoring, mobile cardiac telemetry, and extended holter monitoring for AdventHealth patients.
• Patients will be able to monitor their symptoms in real-time from home through the AdventHealth virtual care center.
• AdventHealth's Central Florida division, sees over 5.7 million patients annually.
• Generally unusual arrhythmias or other monitored symptoms receive immediate communication from providers, enabling greater access to care and, in some cases, earlier diagnoses of serious medical conditions.

4

Rapidly Rising US Population HealthCare Risk

• 900,000 annual deaths due to heart diseases
• 183,000 annual deaths related to AFIB
• 12M AFIB patients by 2030
• 1 of 2 Americans have high BP (116M)
• $147B loss of productivity
• +37M Americans have diabetes
• 96M (1 of 3) Americans are prediabetes - in high risk to develop type 2 diabetes, heart disease and stroke
• 80% don't know they are prediabetes
• $327B is the estimated annual cost for diabetes
• 42% of Americans are obese
• The leading cause of heart disease, stroke, type 2

diabetes and certain types of cancer	https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm

• $173B is the estimated medical cost related to obesity

5